Scorpion Therapeutics Inc. has found compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

A Tisento Therapeutics Inc. patent describes new soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, vascular dementia, ischemic stroke, Leigh syndrome, Pearson syndrome, creatine deficiency syndrome and Alpers syndrome, among others.

Aurigene Oncology Ltd. has disclosed new bicyclic heteroaryl compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors potentially useful for the treatment of cancer.

Eluciderm Inc. has reported new Wnt signaling inhibitors described as potentially useful as wound-healing agents.

Dana-Farber Cancer Institute Inc. has identified alkylamine-containing small-molecule B-cell lymphoma 6 protein (BCL6) degradation inducers potentially useful for the treatment of lymphoma.

Rhythm Pharmaceuticals Inc. has patented new Kir6.2/SUR1 activators reported to be useful for the treatment of disorders of sexual function, hyperinsulinemia, cancer, genitourinary, neurological and cardiovascular disorders.

Raytone Biotechnology Co. Ltd. has described compounds based on oxidative stress and antiamyloid aggregations reported to be useful for the treatment of cataracts and presbyopia.

Zhuhai Yufan Biotechnologies Co. Ltd. has divulged mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease, AIDS, hemolytic anemia, psoriasis, scleroderma, systemic lupus erythematosus and ulcerative colitis, among others.

Allorion Therapeutics (Guangzhou) Co. Ltd. has identified phosphoramidate compounds targeting aldo-keto reductase family 1 member C3 (AKR1C3; 17β-HSD5) reported to be useful for the treatment of cancer.